Chemed Co. (NYSE:CHE) VP Michael D. Witzeman sold 2,174 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $430.00, for a total value of $934,820.00. Following the completion of the sale, the vice president now directly owns 5,175 shares in the company, valued at $2,225,250. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Shares of CHE opened at $436.18 on Thursday. The firm has a market capitalization of $6.85 billion, a price-to-earnings ratio of 36.56, a price-to-earnings-growth ratio of 2.93 and a beta of 1.14. The company has a debt-to-equity ratio of 0.25, a quick ratio of 0.78 and a current ratio of 0.81. Chemed Co. has a one year low of $260.03 and a one year high of $441.48. The stock’s fifty day moving average is $396.70 and its 200-day moving average is $345.80.
Chemed (NYSE:CHE) last issued its quarterly earnings results on Thursday, July 25th. The company reported $3.36 EPS for the quarter, beating analysts’ consensus estimates of $3.09 by $0.27. The company had revenue of $473.60 million for the quarter, compared to analyst estimates of $471.72 million. Chemed had a return on equity of 35.63% and a net margin of 10.94%. The company’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same period last year, the company earned $2.81 earnings per share. Analysts forecast that Chemed Co. will post 13.54 EPS for the current fiscal year.
Several equities research analysts have weighed in on the company. Zacks Investment Research lowered Chemed from a “hold” rating to a “sell” rating in a research report on Thursday, May 9th. Royal Bank of Canada raised their price target on Chemed to $405.00 and gave the company a “sector perform” rating in a report on Monday, July 29th. ValuEngine raised Chemed from a “hold” rating to a “buy” rating in a report on Friday, June 7th. Finally, Oppenheimer raised their price target on Chemed from $400.00 to $430.00 and gave the company an “outperform” rating in a report on Thursday, August 1st. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. Chemed currently has a consensus rating of “Hold” and an average price target of $383.75.
Several institutional investors and hedge funds have recently modified their holdings of CHE. Quadrant Capital Group LLC grew its holdings in Chemed by 184.8% during the first quarter. Quadrant Capital Group LLC now owns 94 shares of the company’s stock worth $26,000 after acquiring an additional 61 shares during the period. Krane Funds Advisors LLC acquired a new position in Chemed during the second quarter worth about $26,000. Bremer Bank National Association acquired a new position in Chemed during the first quarter worth about $29,000. Advisory Services Network LLC grew its holdings in Chemed by 117.9% during the second quarter. Advisory Services Network LLC now owns 85 shares of the company’s stock worth $30,000 after acquiring an additional 46 shares during the period. Finally, Financial Gravity Wealth Inc. acquired a new position in Chemed during the first quarter worth about $49,000. 87.14% of the stock is currently owned by institutional investors.
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates through two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned and independent contractors, and franchised locations.
Read More: Why are percentage decliners important?
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.